The prototypic and broad BH3-mimetic ABT-737 inhibits BCL-2, BCL-W, and BCL-XL and induces cell death in various tumors including HCC, which highly express BCL-XL [20, 21]. This evidence concerns the gene BCL2L1 and hepatocellular carcinoma.